Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Geratherm Medical AG is a global provider of medical technology specializing in the development, manufacturing, and distribution of products focused on healthcare applications. The company's primary function is to provide reliable and innovative solutions for temperature management, respiratory care, and cardiac monitoring. Geratherm's product lines include temporal artery thermometers, blood pressure monitors, and respiratory diagnostic tools used in both clinical and home settings. As part of the healthcare sector, Geratherm Medical AG significantly impacts hospitals, clinics, and individual consumers seeking accurate health monitoring equipment. The firm is known for its commitment to quality and precision, ensuring that its offerings meet stringent safety and efficacy standards. Headquartered in Germany, Geratherm's role in the market is characterized by its focus on improving patient care through cutting-edge technology and its ability to adapt to the evolving demands of the global healthcare landscape.
The business is unprofitable at the operating level (-0.38% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 11.2% YoY with margins expanding 29.1pp. However, free cash flow softened 42%, worth monitoring whether this is timing or structural.
Free cash flow declined 42% versus the prior year, cash generation momentum has weakened.
Profitability & Returns
Revenue (TTM)
€16M
▲ +11.2% YoY
Net Income (TTM)
-€828K
▼ -226.8% YoY
Op. Margin
-0.38%
▲ +29.1pp YoY
ROIC
-0.21%
▲ +11.4pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
€712K
▼ -41.9% YoY
Op. Cash Flow (TTM)
€874K
▼ -78.4% YoY
Net Debt
-€7M
Net Cash Position
Cash & Equiv.
€9M
3Y CAGR: -16.4%
3Y CAGR: +149.2%
Continue Research